Dyadic International, Inc.
DYAIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeDyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. With a market capitalization of $16.0M, it sits in micro-cap territory. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Market Cap
$16.0M
Beta
0.96
P/E (TTM)
—
P/E (Fwd)
-1.25
EPS (TTM)
$-0.23
EPS (Fwd)
$-0.32
ROE
—
ROA
-63.0%
Cash
$3.1M
Total Debt
$5.0M
Free CF
-$4.8M
52W Change
-66.1%
Annual Financials
Cash vs Debt
Where DYAI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, DYAI finished 50.00% below its 150-day moving average ($0.76) and 51.90% below its 200-day moving average ($0.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DYAI overbought or oversold?
At the October 20, 2026 close, DYAI's RSI(14) was 28.6, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $3.1M in cash, though total debt stands at $5.0M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$4.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has pulled back from $2.9M (2022) to $1.2M (2025), a 58% decline worth watching.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Dyadic International, Inc. and its sector.